Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
MemberCocrystal PharmaCocrystal PharmaCocrystal Pharma is a clinical-stage biotechnology company specializing in the discovery and development of novel antiviral therapeutics for serious and chronic viral diseases such as influenza, COVID-19, hepatitis C, norovirus, and other respiratory viruses. The company leverages structure-based drug discovery technology and expertise in structural biology to design direct viral replication inhibitors with broad-spectrum activity. Its pipeline includes candidates in preclinical and clinical development, addressing unmet needs in antiviral medicine.
Cocrystal Pharma is a clinical-stage biotechnology company specializing in the discovery and development of novel antiviral therapeutics for serious and chronic viral diseases such as influenza, COVID-19, hepatitis C, norovirus, and other respiratory viruses. The company leverages structure-based drug discovery technology and expertise in structural biology to design direct viral replication inhibitors with broad-spectrum activity. Its pipeline includes candidates in preclinical and clinical development, addressing unmet needs in antiviral medicine.
Publication Number
US-11752166-B2
Publication Date
2023-09-12
Expiration Date
Abstract
Disclosed herein are combination therapies for use in the treatment or prevention of HCV by administering Compound A and a second HCV inhibitor.
Core Innovation
The document describes a combination HCV therapy for treating hepatitis C virus (HCV) infection in a subject in need thereof. The therapy administers a first therapeutic comprising Compound A and/or a pharmaceutically acceptable salt thereof together with a second therapeutic selected from an NS5B inhibitor and/or an NS5A inhibitor, in amounts effective to treat HCV.
In some embodiments, the combination additionally includes a third therapeutic selected from an NS3A/4A protease inhibitor and ribavirin, also in amounts effective to treat HCV. The disclosed regimens are framed to provide effective antiviral treatment across HCV genotypes 1–6 and across patient categories including naive, non-responder, and cirrhotic status.
The document further describes expected additive or synergistic antiviral effects of Compound A when combined with second inhibitors, compared with monotherapy. Cell-based HCV GT1b replicon combination testing of Compound A with multiple second inhibitors is reported, including use of checkerboard cross design and combination index outcomes using MacSynergy II, indicating additive or minor synergy across NS5B, NS5A, NS3 protease inhibitor, and ribavirin regimens.
Claims Coverage
The document includes three independent claims. Across these claims, the inventive coverage centers on administering Compound A with an NS5B and/or NS5A inhibitor, optionally further including an NS3A/4A protease inhibitor and ribavirin, and on fixed combinations where the second therapeutic is constrained to particular NS5A/NS5B pairings or to glecaprevir+pibrentasvir or velpatasvir+sofosbuvir.
Compound A with an NS5B and/or NS5A inhibitor for treating HCV infection
A method of treating hepatitis C virus (HCV) infection in a subject in need thereof comprising administering to the subject a first therapeutic selected from Compound A and a pharmaceutically acceptable salt thereof and a second therapeutic selected from an NS5B inhibitor and/or an NS5A inhibitor, and optionally a third therapeutic selected from an NS3A/4A protease inhibitor and ribavirin in amounts effective to treat HCV in the subject.
Compound A with an NS5A/NS5B inhibitor combination
A method of treating hepatitis C virus (HCV) infection in a subject in need thereof comprising administering to the subject a first therapeutic selected from Compound A and a pharmaceutically acceptable salt thereof and a second therapeutic selected from a combination of an HCV NS5A inhibitor and an HCV NS5B inhibitor, in amounts effective to treat HCV in the subject.
Compound A with either glecaprevir/pibrentasvir or velpatasvir/sofosbuvir
A method of treating hepatitis C virus (HCV) infection in a subject in need thereof comprising administering to the subject a first therapeutic selected from Compound A, or a pharmaceutically acceptable salt thereof, and a second therapeutic selected from the group consisting of a combination of glecaprevir and pibrentasvir and a combination of velpatasvir and sofosbuvir, in amounts effective to treat HCV in the subject.
Overall, claim coverage protects methods in which Compound A is combined with NS5B and/or NS5A inhibitors for treating HCV infection, with optional inclusion of an NS3A/4A protease inhibitor and ribavirin. Additional coverage is provided for embodiments where the NS5A/NS5B inhibitors are administered as a defined pair, and where the second therapeutic is constrained to either glecaprevir+pibrentasvir or velpatasvir+sofosbuvir.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?